Curium submits NDA for new GEP-NETS treatment
AuntMinnie
JULY 8, 2024
Nuclear medicine firm Curium has submitted a new drug application (NDA) for its lutetium-177 (Lu-177) DOTATATE radiopharmaceutical for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS).
Let's personalize your content